Why Companies Should Pursue True Patient-Centricity
Bringing patients into the drug development process early has proven to save time, money and resources.
Why Companies Should Pursue True Patient-Centricity Read More »
Medicare proposes 2.4% pay bump for inpatient hospitals in 2027, floats mandatory model
Regulators are proposing to send $1.4 billion more to acute care hospitals and debut the first nationwide, mandatory payment model to lower the cost of joint replacements. Hospitals pushed back.
Medicare proposes 2.4% pay bump for inpatient hospitals in 2027, floats mandatory model Read More »
BioNTech, DualityBio tout ‘clinically meaningful’ efficacy for ADC in mid-stage endometrial cancer trial
Trastuzumab pamirtecan, being developed under a 2023 partnership between BioNTech and DualityBio, elicited a 44.1% overall response rate in a Phase 2 trial.
GE HealthCare integrates ultrasound into Medtronic’s Stealth AXiS surgical system
Partnering with GE HealthCare has enabled Medtronic to provide live images to help surgeons assess mid-procedure changes.
GE HealthCare integrates ultrasound into Medtronic’s Stealth AXiS surgical system Read More »
CMS proposes new deadlines for prior authorizations for drugs
Drugs were left out of a 2024 rule streamlining prior authorizations, including by making decisions electronic and requiring payers to turn them around more quickly. The Trump administration is looking to address that gap.
CMS proposes new deadlines for prior authorizations for drugs Read More »
Stryker to buy Amplitude Vascular Systems
Amplitude’s intravascular lithotripsy technology could emerge as a challenger to Shockwave IVL, Leerink Partners analyst Mike Kratky wrote.
Allogene stock sails after CAR T clears residual lymphoma in early data cut
Pivotal findings for the off-the-shelf cell therapy surpassed William Blair’s expectations and sent Allogene Therapeutics’ stock up more than 50% in pre-market trading Monday morning.
Allogene stock sails after CAR T clears residual lymphoma in early data cut Read More »
USP adds Tamiflu, Trulicity to vulnerable list as upstream analysis reshapes supply concerns
Almost half of the top 100 medicines vulnerable to supply disruptions in the U.S. have at least one key starting material with a single source country, according to a new report from United States Pharmacopeia.
IDEAYA and Servier’s eye cancer drug heads to FDA after delivering ‘best in class’ efficacy
Darovasertib, in combination with crizotinib, more than doubled progression-free survival in a registrational trial, leading Truist analysts to declare a “best-in-class efficacy profile” for the PKC inhibitor.
Revolution rises 40% as pancreatic cancer drug doubles survival
In a difficult disease, Revolution Medicines achieved what the pancreatic cancer community has long desired: a significant improvement in survival. The Phase 3 results will support global regulatory filings.
Revolution rises 40% as pancreatic cancer drug doubles survival Read More »